Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT

Hye Lim Park, Ie Ryung Yoo, Sung Hoon Kim, Sohee Lee
Departments of Radiology and Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

INTRODUCTION

Hyperparathyroidism is the most common and first manifestation of multiple endocrine neoplasia type 1 (MEN1), most of which are due to hyperplasia of multiple parathyroid glands [1]. Treatment of hyperparathyroidism in MEN1 patients consists of surgical removal of the parathyroid glands. However, the rate of persistent or recurrent hyperparathyroidism after primary operation is high, for which one of the reasons is the presence of supernumerary or ectopic parathyroid gland [1]. For complete surgical removal of parathyroid glands, precise localization using an appropriate imaging method is needed. Technetium-99m (Tc-99m) sestamibi scintigraphy is a highly sensitive diagnostic tool for the detection of hyperfunctioning parathyroid glands. Tc-99m sestamibi single-photon emission computed tomography (SPECT) or single-photon emission computed tomography/computed tomography (SPECT/CT) can improve both sensitivity and specificity compared to planar scan [2]. We report here a MEN1 patient with anterior mediastinal parathyroid adenoma who underwent successful surgical excision after localization via SPECT/CT. To our knowledge, this is the first reported case in the literature of mediastinal parathyroid adenoma in MEN1 patient visualized by Tc-99m sestamibi SPECT/CT.

CASE REPORT

A 51-year-old female reported to the Endocrinology Department...
ment for genetic counseling. She was the eldest of the 3 sisters, of whom had been diagnosed with MEN1. The middle sister (46 years of age) had hyperparathyroidism and a pancreatic neuroendocrine tumor. The youngest sister (42 years of age) had hyperparathyroidism, pituitary microadenoma, and a pancreas neuroendocrine tumor. Upon examination of the MEN gene (11q13), mutations c.669+3A>G (intron 3), which results in a splicing defect, and missense variation c.1636G>A (exon 10) were confirmed. In a screening test for MEN1, blood sampling and imaging studies were performed. Intact parathyroid hormone (iPTH) (731.59 pg/mL) and serum calcium (12.5 mg/dL) levels were elevated, and 25-hydroxy vitamin D (15.21 ng/dL) level was decreased. Tc-99m sestamibi scintigraphy was performed for diagnosis of hyperfunctioning parathyroid gland (Fig. 1). Four-hour late imaging showed focal uptake in the right upper and lower thyroid beds, suggestive of hyperfunctioning parathyroid glands. To exclude incidental ectopic parathyroid glands, a planar chest image was obtained, and focal hot uptake was seen in the mediastinum. When additional SPECT/CT was performed to localize the mediastinal hot uptake, a lobulated mass with focal sestamibi uptake was noted in the mediastinal left paraaortic region (Fig. 2). There was no other abnormality suggestive of MEN1 in blood tests or imaging studies. Total parathyroidectomy with autotransplantation of a parathyroid

![Fig. 1. Technetium-99m sestamibi scan. (A) On early 15-minute image of anterior neck, diffuse thyroid activity is seen. (B) On late 4-hour image, thyroidal activity is washed out and small focal uptake areas are noted in upper and lower portion of right thyroid bed (arrows). (C) On the chest planar image for excluding ectopic parathyroid gland, focal hot uptake is noted in mid chest region.](image1)

![Fig. 2. Technetium-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT). (A) Focal hot uptake is noted in anterior mediastinum on SPECT image. (B, C) A lobulated nodular lesion with increased sestamibi uptake is seen in left paraaortic region on CT and SPECT/CT images.](image2)
gland on the left forearm and video-assisted thoracoscopic surgery on an anterior mediastinal mass were performed. Final pathology revealed hyperplasia of bilateral superior and inferior parathyroid glands and a parathyroid adenoma of anterior mediastinal mass. The size of the hyperplasia involving the four parathyroid glands was about 1.0 cm × 1.0 cm, and the size of the parathyroid adenoma was 3.5 cm × 2.2 cm. After operation, the patient’s iPTH and serum calcium level were restored to normal.

DISCUSSION

MEN1 is an autosomal dominant familial tumor syndrome in which tumors can develop in the endocrine system, mostly in the anterior pituitary gland, parathyroid gland and pancreatic islet cells [3]. Hyperparathyroidism resulting from parathyroid adenoma or hyperplasia occurs in most patients and is typically the first manifestation of MEN1 [4]. Hyperparathyroidism manifests in most patients by their third decade of life [5]. However, as in our case patient, there can be a long asymptomatic period even through the biochemical changes of hyperparathyroidism and decreased bone mass [6]. The treatment of choice for hyperparathyroidism in MEN1 is surgical removal of parathyroid glands. Subtotal parathyroidectomy or total parathyroidectomy with autotransplantation of parathyroid tissue is usually recommended [7]. After surgical excision of parathyroid glands, persistent or recurrent hyperparathyroidism can result from supernumerary or ectopic parathyroid glands, regrowth of remnant parathyroid glands or hyperfunctioning autograft tissue [1]. The major cause of persistent or recurrent hyperparathyroidism is ectopic or supernumerary parathyroid gland. Therefore, precise localization of parathyroid glands is essential for complete surgical removal.

Parathyroid glands originate from the third and fourth branchial pouches and usually are located posterior to the thyroid. Superior parathyroid glands arise from the fourth branchial pouch and migrate with the thyroid gland. Inferior parathyroid glands arise from the third branchial pouch and migrate with the thymus, a relatively longer distance than the movement of the superior parathyroid glands. Therefore, the locations of inferior parathyroid glands are more variable [8]. Ectopic inferior parathyroid glands can be located in the cervical portion of the thymus, the posterior aspect of the middle third of the thyroid gland, the anterior mediastinum, the intrathyroidal region, or along the carotid sheath. Among these locations, ectopic parathyroid glands in the anterior mediastinum are rare, representing about 3.9%–5% of incidences [9]. Ectopic or supernumerary parathyroid glands are more common in MEN patients than in sporadic hyperparathyroidism patients [10].

Tc-99m sestamibi scintigraphy is regarded as the best imaging modality for identification of hyperfunctioning parathyroid tissue. It shows only hyperfunctioning parathyroid tissue, not normal parathyroid glands. Therefore, it is helpful for discriminating hyperfunctioning parathyroid glands from normal parathyroid glands. Tc-99m sestamibi parathyroid scintigraphy is performed in 2 phases on the anterior neck using a pinhole collimator: early (5–15 minutes) images and late (2–4 hours) images after intravenous injection of Tc-99m sestamibi. A chest image must also be obtained using a parallel collimator in order to detect incidental or unsuspected mediastinal ectopic parathyroid tissue. Obtaining chest planar images is a good method to exclude ectopic parathyroid tissue without additional radiation exposure and cost. Therefore, chest images should be obtained before the parathyroidectomy is scheduled for the patient.

Precise localization of hyperplastic parathyroid glands or parathyroid tumors is also important to improve surgical outcome. It is better to use SPECT/CT for precise localization of parathyroid glands. Large-sized adenomas or hyperplasia can be detected or localized easily by CT or ultrasonography; however, it is difficult to identify small parathyroid tissue. Tc-99m sestamibi SPECT or SPECT/CT show high sensitivity and specificity for diagnosis of hyperfunctioning parathyroid glands even of small size [8].

In conclusion, we report a case of a MEN1 patient with anterior mediastinal parathyroid adenoma that was successfully removed following localization via Tc-99m sestamibi scintigraphy and SPECT/CT.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Kivlen MH, Bartlett DL, Libutti SK, Skarulis MC, Marx SJ, Simonds WF, et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 2001;130:991-8.
2. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)
3. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 2010;24:355-70.
4. Thakker RV. Multiple endocrine neoplasia: syndromes of the twentieth century. J Clin Endocrinol Metab 1998;83:2617-20.
5. Benson L, Ljunghall S, Akerstrom G, Oberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med 1987;82:731-7.
6. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 1999;134:1119-23.
7. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 2007;246:1075-82.
8. Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. Radiographics 2008;28:1461-76.
9. Flint PW, Haughey BH, Lund VJ, Niparko JK, Robbins KT, Thomas JR. et al. Cummings otolaryngology: head and neck surgery. 6th ed. Philadelphia (PA): Elsevier/Saunders; 2015.
10. Arnalsteen LC, Alesina PF, Quireux JL, Farrel SG, Patton FN, Carnaille BM, et al. Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 2002;132:1119-24.